The US Department of Commerce has left unresolved the exact circumstances in which the federal government can require a patent owner or licensee to share its patent rights with another party, but its suggestion that drug pricing is not likely to be a factor for pharma patents will surely drive further debate over the issue before regulations are implemented.
On 24 April, the Commerce Department's National Institute of Standards and Technology (NIST) issued a final Green Paper addressing the...